TTNP - שווי שוק לנפח מכירות Titan Pharmaceuticals Inc.

Titan Pharmaceuticals is establishing strategic partnerships to integrate ProNeura systems into addiction therapy. The company's capitalization is based on the implementation of long-acting implants. The price-to-sales ratio dynamics reflect current market phases, where the parameter value equals 43.80. The firm's environmental policy remains formal, limited to standard waste disposal within its laboratory complexes.

Titan Pharmaceuticals maintains a high business valuation driven by its technological advantage in developing ProNeura implants for long-term drug release. GURU.Markets analysts utilize the enterprise value-to-revenue ratio to determine the premium paid for every dollar of sales and identify the risk of overpayment relative to industry norms, monitoring the stability of this balance on the chart.